Clinical Trial Update: Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the efficacy and safety of RPH-104 for Schnitzler syndrome (including associated urticarial vasculitis with an IgM component…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schnitzler Syndrome
• Urticarial Vasculitis

Drugs mentioned

• RPH-104

Snippet

Sponsor: R-Pharm Overseas, Inc. | Conditions: Schnitzler Syndrome, Urticarial Vasculitis With Monoclonal Immunoglobulin M Component, Schnitzler (Disorder) | Phase 2 | Status: WITHDRAWN